Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis.

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Poly(ADP-ribose) polymerase (PARP) inhibitors are established first-line maintenance therapy for advanced epithelial ovarian cancer (EOC) post-platinum chemotherapy.
• While clinical trials show efficacy for olaparib and niraparib, real-world data are limited.

Purpose of the Study:

• To evaluate the real-world effectiveness and safety of first-line maintenance olaparib and niraparib in advanced EOC.
• To assess progression-free survival (PFS) and overall survival (OS) outcomes in a diverse patient cohort.

Main Methods:

• Retrospective, multicenter study of 179 advanced EOC patients receiving first-line maintenance olaparib or niraparib.
• Data collected included clinical, pathological, and molecular information, focusing on BRCA mutation status.
• Progression-free survival (PFS) was the primary endpoint, analyzed using Kaplan-Meier methods.

Main Results:

• Estimated 24-month PFS rates were 64.0% for the overall cohort.
• Patients with BRCA mutations showed robust PFS, with pathogenic variants correlating to longer PFS.
• Adverse events were manageable, predominantly hematologic toxicities; dose interruptions were more common with niraparib.

Conclusions:

• First-line maintenance olaparib and niraparib demonstrate durable PFS benefits in real-world advanced EOC patients.
• Effectiveness is particularly pronounced in patients with pathogenic BRCA mutations.
• These PARP inhibitors exhibit manageable safety profiles in routine clinical practice.